Loading clinical trials...
Loading clinical trials...
A Multiple-Dose, Randomized, Placebo-Controlled, Study of LY3462817 or LY3509754 in Patients With Psoriasis
Conditions
Interventions
LY3462817 - IV
LY3462817 - SC
+4 more
Locations
13
United States
Dermatology Associates - Los Angeles
Los Angeles, California, United States
Miami Dermatology and Laser Research
Miami, Florida, United States
Advanced Pharma Clinical Research
Miami, Florida, United States
ForCare Clinical Research
Tampa, Florida, United States
Avita Clinical Research
Tampa, Florida, United States
Meridian Clinical Research
Baton Rouge, Louisiana, United States
Start Date
November 20, 2019
Primary Completion Date
February 9, 2022
Completion Date
February 9, 2022
Last Updated
March 15, 2022
NCT07474792
NCT06857942
NCT06979453
NCT07471048
NCT07449234
NCT07116967
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions